Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register

OBJECTIVE: To estimate the effects of Janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi), other biologic(b) or conventional synthetic(cs) disease-modifying antirheumatic drugs (DMARDs) on the risk of major adverse cardiovascular events (MACE) in patients with rheumatoid arthrit...

Descripción completa

Detalles Bibliográficos
Autores principales: Meissner, Yvette, Schäfer, Martin, Albrecht, Katinka, Kekow, Joern, Zinke, Silke, Tony, Hans-Peter, Strangfeld, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603345/
https://www.ncbi.nlm.nih.gov/pubmed/37880180
http://dx.doi.org/10.1136/rmdopen-2023-003489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603345/
https://www.ncbi.nlm.nih.gov/pubmed/37880180
http://dx.doi.org/10.1136/rmdopen-2023-003489

Ejemplares similares